Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2021
Event: Settlement of patent infringement litigation against Ivantis, Inc.
Key Financial Metrics
This filing reports a specific settlement agreement rather than periodic financial results. Key financial terms include:
- Total Cash Settlement: $60 million.
- Payment Schedule: $30 million due on or before December 31, 2021; remaining $30 million due by December 31, 2022.
- Royalty Agreement: 10% of Ivantis' Hydrus Microstent U.S. sales and international sales supplied from the U.S. through April 26, 2025, subject to a per-unit minimum.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the termination of the patent infringement lawsuit filed by Glaukos against Ivantis on April 14, 2018. The lawsuit alleged infringement of U.S. Patent Nos. 6,626,858 and 9,827,143 regarding Ivantis' Hydrus Microstent device. The trial, originally scheduled for September 28, 2021, will be dismissed with prejudice upon receipt of the first upfront payment.
Outlook, Risks, and Management Commentary
- Legal Resolution: The parties agreed to mutual licenses and covenants not to sue regarding the Hydrus Microstent and Glaukos' micro-stent devices.
- Future Revenue Stream: The settlement establishes a recurring royalty revenue stream tied to Ivantis' sales through 2025.
- Contingencies: The dismissal of the lawsuit is contingent upon Glaukos receiving the first $30 million payment.
Investor Verification Checklist
- Confirm the receipt of the initial $30 million payment by December 31, 2021.
- Monitor future quarterly reports for the recognition of royalty revenue from Ivantis.
- Verify the specific terms of the "per-unit minimum payment" mentioned in the royalty agreement.
- Review subsequent filings for any updates on the second $30 million payment due in 2022.